9,157 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Acquired by Syon Capital LLC

Syon Capital LLC acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 9,157 shares of the biopharmaceutical company's stock, valued at approximately $276,000.

A number of other institutional investors have also recently made changes to their positions in the company. Barclays PLC boosted its stake in TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after buying an additional 158,323 shares during the last quarter. Synovus Financial Corp bought a new position in shares of TG Therapeutics during the 3rd quarter valued at approximately $465,000. Franklin Resources Inc. grew its holdings in shares of TG Therapeutics by 3.8% in the third quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company's stock valued at $2,945,000 after purchasing an additional 4,756 shares in the last quarter. Principal Financial Group Inc. lifted its position in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock valued at $16,859,000 after acquiring an additional 270,286 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Trading Up 4.4 %

TGTX stock traded up $1.83 during mid-day trading on Tuesday, reaching $43.86. The company had a trading volume of 2,692,978 shares, compared to its average volume of 3,079,374. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a market capitalization of $6.96 billion, a PE ratio of -438.56 and a beta of 2.14. The firm has a 50 day moving average of $37.40 and a 200 day moving average of $32.73. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.96.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.